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A polyalanine peptide derived 
from polar fish with anti-infectious 
activities
Marlon H. Cardoso2,3,4, Suzana M. Ribeiro2,3, Diego O. Nolasco1,6, César de la Fuente-Núñez7,9, 
Mário R. Felício8, Sónia Gonçalves8, Carolina O. Matos5, Luciano M. Liao5, Nuno C. Santos8, 
Robert E. W. Hancock7, Octávio L. Franco1,2,3,4 & Ludovico Migliolo2,3
Due to the growing concern about antibiotic-resistant microbial infections, increasing support has 
been given to new drug discovery programs. A promising alternative to counter bacterial infections 
includes the antimicrobial peptides (AMPs), which have emerged as model molecules for rational 
design strategies. Here we focused on the study of Pa-MAP 1.9, a rationally designed AMP derived 
from the polar fish Pleuronectes americanus. Pa-MAP 1.9 was active against Gram-negative planktonic 
bacteria and biofilms, without being cytotoxic to mammalian cells. By using AFM, leakage assays, CD 
spectroscopy and in silico tools, we found that Pa-MAP 1.9 may be acting both on intracellular targets 
and on the bacterial surface, also being more efficient at interacting with anionic LUVs mimicking 
Gram-negative bacterial surface, where this peptide adopts α-helical conformations, than cholesterol-
enriched LUVs mimicking mammalian cells. Thus, as bacteria present varied physiological features that 
favor antibiotic-resistance, Pa-MAP 1.9 could be a promising candidate in the development of tools 
against infections caused by pathogenic bacteria.
In recent decades, improvements in the prevention and treatment of infectious diseases caused by pathogenic 
microorganisms has been of great importance in reducing morbidity and mortality, leading to a better quality 
of life and longer life expectancy1. However, antibiotics have been widely and sometimes indiscriminately used, 
which has resulted in the emergence of pathogens with multi-drug resistance in a wide range of bacterial spe-
cies, including Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and many 
other species2. Conversely, the rate of discovery of new antibiotics has steadily plummeted. Additionally, the 
occurrence and treatment of biofilm infections has appeared as one of the biggest challenges in the medical field 
with no available antibiotics that were developed to treat such infections. Biofilms are characterized as being a 
structured consortium of microorganisms connected by a complex matrix composed of polysaccharide(s), pro-
tein and DNA, that grows on biotic or abiotic surfaces via a multistage process3. It has been established that 
pathogenic bacteria are predominantly organized in biofilms, which are the cause of 65% to 80% of all bacterial 
infections in humans3,4. Biofilm growth represents a unique growth state whereby bacteria have major physio-
logical and organizational differences, in particular leading to 10- to 1000- fold increased (adaptive) resistant to 
conventional antibiotics3,4.
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In this context, investigating and improving on natural compounds has been of great interest in the search 
for promising alternatives to conventional medicines. In recent years, cationic amphipathic peptides termed 
anti-microbial peptides (AMPs) have been widely investigated as a promising alternative for the treatment of 
infections caused by pathogenic microorganisms5. These molecules have been isolated from a wide number of 
organisms including plants6, animals7 and bacteria8. These peptides tend to have multiple targets that can include 
the cytoplasmic membrane permeability barrier, macromolecular processes dependent on the membrane, includ-
ing cell wall biosynthesis and cell division, and/or other intracellular targets including RNA and protein syn-
thesis5. Moreover, recent evidence indicates that AMPs’ ability to act on intracellular targets can either occur as 
a major mechanism of action after having crossed the membrane without causing disruptive processes, or as a 
secondary and/or additional mechanism to membrane disruption9.
Currently, some of the largest challenges in working with AMPs involve their cytotoxicity against mamma-
lian cells, as well as their cost of production. Thus, the rational design of AMPs has gained great prominence in 
the scientific field, aiming to develop AMPs that are more active, less cytotoxic and possible to produce on an 
industrial scale10. Early studies of rational design played an important role in the identification of optimal AMP 
physicochemical properties, such as appropriate hydrophobicity, charge and amphipathic structural arrangement, 
which are all directly related with their antimicrobial activities. Template-based designs taking in account charge 
and amphipathicity have also been used based on modified amino acid residues of well-known AMPs in order to 
improve their activities5. Jiang and co-workers11 have recently introduced a new concept of template-based design 
involving the arrangement of lysine and arginine residues in the center of the non-polar region of amphipathic 
α -helical AMPs in order to enhance peptide’s selectivity against both eukaryotic and prokaryotic cell membranes. 
In addition to these strategies, biophysical studies have been used to evaluate AMP activities and design improved 
analogues by predicting and characterizing their structures in different environments, as well as performing 
molecular modelling, dynamics and docking simulations at atomic levels5.
This work focuses on a novel polyalanine-rich cationic AMP, named Pa-MAP 1.9, that was rationally designed 
based on a synthetic multifunctional peptide (Pa-MAP) derived from HPLC-8, a peptide originally isolated from 
the polar fish Pleuronectes americanus12. Here, we report the antimicrobial activities of this peptide, mainly against 
Enterococcus faecalis, S.aureus, E. coli and K. pneumoniae planktonic bacteria, as well as K. pneumoniae and E. coli 
biofilms. Furthermore, biophysical experiments, using circular dichroism (CD), fluorescence spectroscopy and 
atomic force microscopy (AFM), in combination with in silico studies such as molecular modelling, dynamics and 
docking, were performed to obtain insights into the structure of Pa-MAP 1.9, as well as its mechanism of action.
Results
Pa-MAP 1.9 synthesis and mass spectrometry analysis. Pa-MAP 1.9 (NH2-LAAKLTKAATKLTAALT 
KLAAALT-COOH) was designed, and synthetized by Fmoc strategy loosely based on the sequence of a previ-
ously described multifunctional peptide, Pa-MAP (NH2-HTASDAAAAAALTAANAAAAAAASMA-COOH)12, 
in which the net charge and hydrophobic moment were increased, hydrophobic amino acid frequency was 
decreased (since high hydrophobicity favors toxicity) and alanine residues were distributed along the molecule 
in order to obtain a linear cationic peptide with predicted helical stretches. MALDI-ToF analysis showed greater 
than 95% purity and an ion mass of 2668.0 m/z, in agreement with the theoretical calculated molecular mass for 
this peptide (Fig. S1).
In vitro antimicrobial assays. Pa-MAP 1.9 was evaluated for its ability to inhibit the growth of different 
bacteria grown planktonically and in biofilms. Pa-MAP 1.9 was able to inhibit the growth of Enterococcus fae-
calis, E. coli and K. pneumoniae planktonic cells with minimal inhibitory concentrations (MICs) of 1.5, 6–12 
and 24–96 μ M, respectively (Table 1). However, no antibacterial activity was observed against P. aeruginosa and 
S. aureus, even at the maximum concentration used for this assay (115 μ M). Against bacteria in their biofilm 
growth state, Pa-MAP 1.9 was considerably more potent, with (MBICs) of 3.0 and 1.1 μ M (Table 1) against 
E. coli and K. pneumoniae biofilms respectively. At these same concentrations, flow cell analysis revealed that 
pre-formed E. coli and K. pneumoniae biofilms (Fig. 1a,c) were strongly or completely inhibited, with a strong 
decrease in biofilm volume and height (Fig. 1b,d).
Hemolytic and cytotoxicity assays. Pa-MAP 1.9 did not show neither hemolytic activity against human 
erythrocytes or cytotoxic effects against RAW 264.7 monocyte cell line up to 115 μ M, the maximum concentra-
tion used in the bioassays (Table 1).
Atomic force microscopy analysis. AFM was used to image the possible AMP-induced damage of the 
Gram-negative bacterial envelope. At 6 μ M (MIC), Pa-MAP 1.9 induced slight morphological changes in the 
form of increased surface roughness in E. coli (Fig. 2b), relative to the untreated control (Fig. 2a). Damage was 
more evident at 300 μ M (50-fold the MIC), where substantial bacterial surface disruption was observed (Fig. 2c).
Permeabilization of lipid vesicles. The ability of Pa-MAP 1.9 to disrupt large unilamellar vesicles 
(LUVs) with compositions roughly mimicking bacterial membranes was also analyzed. Vesicles were prepared 
with encapsulated carboxyfluorescein (CF), and then incubated with Pa-MAP 1.9 concentrations up to 1.0 μ M. 
The percentages of leakage were evaluated as previously described13, by assessing the differences over time 
in the emission of CF (which fluoresces more strongly upon leakage from the vesicles), with 100% of leakage 
corresponding to full disruption of lipid vesicles. The data showed that the peptide induced leakage of vesi-
cles containing anionic lipids such as 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′ –sn-glycerol) (POPG), 
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) or lipopolysaccharide (LPS), requiring only 
0.25 μ M peptide for almost complete permeabilization (Fig. 3a). Moreover, at 0.75 μ M of Pa-MAP 1.9, full leak-
age was reached for all other vesicles containing anionic phospholipids (Fig. 3b). In contrast, zwitterionic vesicles 
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of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or POPC/Cholesterol (Chol) (70:30) clearly 
demonstrated reduced leakage, even at the maximum concentration used for this experiment (Fig. 3a,b). The 
results obtained demonstrate the specificity of the AMP for negatively charged membranes, such as those from 
Gram-negative bacteria and are consistent with the lack of toxicity for mammalian cells, which contain largely 
neutral or zwitterionic lipids on their external leaflet.
Structural analysis. Circular dichroism spectroscopy studies were performed in water, 2,2,2-trifluoroethanol 
(TFE) 50% (v:v) and sodium dodecyl sulfate (SDS) 28 mM. When analyzed in water, the peptide showed no stable 
at pH values ranging from 3 to 10 (Fig. 4a). However, at pH 11 this Pa-MAP 1.9 produced a CD spectrum char-
acteristic of an α -helix conformation, with two negative bands at ~205 and ~222 nm, presenting 14% of ellipticity 
(Fig. 4a). When analyzed in 50% TFE, Pa-MAP 1.9 adopted a well-defined α -helix structure at all pH values 
presenting a positive band at 190 nm and two negative bands at ~205 and ~222 nm (Fig. 4b). Similar results were 
observer for the CD spectrum in anionic lipid-like environment, where the same positive and negative bands 
could be observed, indicating helical conformation (Fig. 4c).
To obtain insights into the three-dimensional structure of Pa-MAP 1.9, molecular modelling simulations were 
performed. The lowest free-energy theoretical model for Pa-MAP 1.9 revealed a well-defined α -helical confor-
mation (Fig. 5b), and also revealed an amphipathic character (Fig. 5c) when modelled based on the antifreeze 
peptide (PDB code: 1wfa) isolated from P. americanus, which presented 58% identity over part of its sequence 
with the Pa-MAP 1.9 primary sequence (Fig. 5a). When evaluated using PROCHECK14, the average score for 
dihedral angles (φ -ψ , χ and ω ), jointly with the main-chain covalent forces for the best model, was 0.23, which 
is within the expected range for a reliable structure. Moreover, a Ramachandran plot showed that 100% of the 
amino acid residues of Pa-MAP 1.9 were located in the most favorable regions. Furthermore, three-dimensional 
structural superposition (3DSS) analysis revealed that the root mean square deviation (RMSD) between the the-
oretical and experimental models was equal to 0.567 Å. Based on those data, this model was selected for further 
in silico studies.
Like the CD analysis, molecular dynamics simulations of the peptide were implemented in three different 
environments including pure water, water and TFE mixture 50% (v:v) and water where the peptide was in contact 
with an SDS micelle. The simulations were performed to better understand the behavior of the three-dimensional 
theoretical structure of the above-described Pa-MAP 1.9 in different environments. After 100 ns of molecular 
dynamics simulations in water, it was possible to observe high values of RMSD and root mean square fluctuation 
(RMSF), revealing the instability of Pa-MAP 1.9 in this environment. In addition, it was observed a decrease 
in the radius of gyration (approximately from 1.3 to 0.6 nm), as well as in the solvent-accessible surface area 
(SASA) (Fig. 6a). These parameters, allied to the three-dimensional structures observed throughout the simula-
tion, revealed that, consistent with the CD spectra, Pa-MAP 1.9 seems to lose its α -helical structure in water, also 
tending to hide its hydrophobic amino acid residues by adopting a coil conformation with a short central α -helix 
since the 20 ns of simulation (Fig. 7a). It can also be associated with a decrease of approximately 0.8 nm2 in the 
SASA (Fig. 6a). On the other hand, simulations performed in water and TFE demonstrated that, in this solvent, 
Pa-MAP 1.9 was able to maintain its initial structure during the 100 ns, presenting only a few structural changes 
at the N-terminus (Fig. 7b). In comparison with the simulation in water, it was also possible to note decreased 
RMSD, RMSF, radius of gyration and SASA values, indicating improved structural stability in TFE (Fig. 6b). 
As expected, simulations in the presence of a micelle containing 128 SDS residues confirmed the preference of 
Pa-MAP 1.9 for amphipathic anionic environments, preserving its α -helical structure. In this simulation, as for 
50% TFE, only a slight RMSD variation of 0.3 nm was observed, stabilizing then between 0.4 and 0.6 nm, indicat-
ing few deviations in the input and output structures along the 100 ns (Fig. 6c). Moreover, the radius of gyration 
Bacterial strains MIC for Pa-MAP 1.9 (μM)
Enterococcus faecalis (ATCC 19433) 1.5
Escherichia coli (ATCC 8739) 6
Escherichia coli (KPC 001812446) 6
Escherichia coli (KPC 002101123) 12
Klebsiella pneumoniae (ATCC 13883) 24
Klebsiella pneumoniae (KPC 002210477) 24
Klebsiella pneumoniae (KPC 001825971) 96
Pseudomonas aeruginosa (ATCC 27853) > 115
Staphylococcus aureus (ATCC 25923) > 115
Bacterial strains MBIC (μ M)
Escherichia coli (ATCC O157) 3
Klebsiella pneumoniae (KPC 001825971) 1.1
Cell line Cytotoxic activity (μ M)
RAW 264.7 (mouse leukemic monocyte macrophage) > 115
Cell type Hemolytic activity (μ M)
Human erythrocytes > 115
Table 1.  Antibacterial, anti-biofilm, cytotoxic and hemolytic activities of Pa-MAP 1.9.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:21385 | DOI: 10.1038/srep21385
was also equivalent to that for TFE simulation, remaining around 1.2 nm (Fig. 6c). In addition, SASA seemed to 
be conserved in these two simulations, varying from 19 to 23 nm during the 100 ns (Fig. 6c). However, contrary 
to what was obtained in 50% TFE, a more significant fluctuation could be observed at the C-terminus region of 
Pa-MAP 1.9 when in contact with SDS micelles, as demonstrated in Figs 6c and7c.
By using our best theoretical model for Pa-MAP 1.9, we also predicted the affinity and atomic interactions of 
this peptide with mimetic membranes containing the same lipid compositions experimentally tested on the leak-
age studies. Fifty runs of molecular docking were performed, and all peptide/membrane complexes were ranked 
by their affinity, in kcal.mol−1. The best affinity values for Pa-MAP 1.9 in POPC/POPS (Fig. 8a) and Pa-MAP 1.9 
in POPC/Chol (Fig. 8b) were − 5.4 and − 3.7 kcal.mol−1, respectively, corroborating our experimental results, 
wherein Pa-MAP 1.9 seemed to interact better with anionic vesicles and Gram-negative bacteria with anionic 
lipid compositions. Furthermore, in both complexes, Pa-MAP 1.9 maintained a well-defined α -helical conforma-
tion during the simulations (Fig. 8a,b). In the complex of Pa-MAP 1.9 with POPC/POPS it was possible to predict 
10 interactions (Fig. 8c) divided into hydrogen bonds (HB), involving nitrogen (N), oxygen (O/OG1) atoms of 
Leu1, Thr10, Lys11,18 and Ala15,22 from Pa-MAP 1.9, and saline bonds (SB), involving positively charged nitro-
gen atoms of the side chain (NZ) of Lys4,7,11,18 from Pa-MAP 1.9, ranging from 2.8 to 3.6 Å of distance (Table 2). 
On the other hand, in the complex of Pa-MAP 1.9 with POPC/Chol, only 6 HBs could be observed (Fig. 8d), 
involving O/OG1 atoms of Ala2 and Thr6,10,13,17,28 from Pa-MAP 1.9 and oxygen atoms (O3) from cholesterol, 
with distances between 2.7 and 3.4 (Table 2).
Discussion
Here we describe the functional and structural characterization of Pa-MAP 1.9, a rationally-designed cati-
onic AMP based on a multifunctional peptide analogue from P. americanus, denominated Pa-MAP12. In our 
Figure 1. Flow-cell analysis of E. coli and K. pneumoniae biofilm formation in the absence and presence of 
Pa-MAP 1.9. Pre-formed E. coli biofilm before (a) and after (b) treatment with 3.0 μ M of Pa-MAP 1.9 (b). Pre-
formed K. pneumoniae biofilm before (c) and after (d) treatment with 1.1 μ M of Pa-MAP 1.9.
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antibacterial assays, Pa-MAP 1.9 revealed better activities mainly against Gram-negative bacterial strains (E. 
faecalis, E. coli and K. pneumoniae), with lower MIC against E. coli (6 μ M) when compared with its precursor 
Pa-MAP (30 μ M)12. Similar enhanced activities against Gram-negative strains have also been reported for other 
AMPs isolated or derived from the winter flounder P. americanus, as it is the case of pleurocidin, a cationic 
α -helical peptide with high activities against E. coli and Pseudomonas aeruginosa, with MIC values below 1 μ M16. 
Moreover, other fish derived AMPs, such as pardaxin (Purdachirus marmorutus) and piscidins-1, -2, -3 and -4 
Figure 2. Atomic force microscopy (AFM) images of E. coli in the absence and presence of Pa-MAP 1.9. 
Untreated bacteria (control) (a), bacteria treated with 6 μ M (b) and 300 μ M (c) of Pa-MAP 1.9. Total scanning 
area per image: 4 × 4 μ m2; scale bar: 1 μ M.
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(Morone chrysops; Morone saxatilis), were also active against the human pathogens E. coli, Acinetobacter calcoace-
ticus, P. aeruginosa, S. typhimurium and Shigella flexneri18,20.
In addition to direct antibacterial assays, we also studied the antimicrobial ability of Pa-MAP 1.9 in prevent-
ing biofilm growth, as well as combating pre-formed bacterial biofilms, since different physiological conditions 
occur in these consortiums when compared to planktonic bacteria, and this leads to increased antibiotic resist-
ance. Previous studies have shown that anti-biofilm activity is independently determined compared to antibacte-
rial activity against planktonic (free-swimming) bacteria. These assays revealed that Pa-MAP 1.9 is a promising 
anti-biofilm peptide with activity at concentrations 90-fold lower than the MIC against one strain of Klebsiella 
pneumoniae. Similar to our results, Tao and colleagues15 described the anti-biofilm potential of another P. ameri-
canus derived-peptide (pleurocidin) in combating Streptococcus mutans biofilm, causing a reduction in S. mutans 
biomass upon treatment with 11.8 μ M of the peptide. In addition, a study performed by Choi and Lee16 reported 
that, below 0.7 μ M, pleurocidin could inhibit pre-formed E. coli and P. aeruginosa biofilms, causing biomass 
reductions of 22.4 and 48.3%, respectively. Interestingly, the concentration of Pa-MAP 1.9 required to combat E. 
coli and K. pneumoniae biofilms were lower than its MIC values for the two studied strains. Similar findings were 
previously made for other small synthetic cationic peptides (IDR-1018, and DJK-6), in circumstances where MIC 
values against K. pneumoniae could not be determined (> 64 μ g.mL−1), but relevant anti-biofilm properties were 
detected at 2–4 μ g.mL−1 (MBIC)21. Flow cell experiments showed even better results, with just 2 μ g.mL−1 of IDR-
1018 and DJK-6 being necessary to eliminate most pre-existing K. pneumoniae biofilms21. These findings were 
consistent with the concept that anti-biofilm peptides act by several mechanisms that include dispersing bacterial 
biofilms and triggering death of cells within biofilms, but that these activities involve independent mechanisms 
from those determining AMP activity.
When evaluated with regard to its potential for causing morphological damage to the surface of E. coli, 
Pa-MAP 1.9 showed dose-dependent action. Below its MIC, only slight changes were observed, suggesting that 
Pa-MAP 1.9 might insert into the E. coli cytoplasmic membrane and translocate to act on intracellular targets. 
However, substantial cell damage was observed upon 50-fold increasing its concentration suggesting lytic activ-
ity at concentrations above the MIC22. This behavior was also described for Sub3, an AMP optimized based 
on bovine bactenecin23 whereby it was found that Sub3 antimicrobial activity is intrinsically related to mem-
brane binding and its cell-penetrating ability, since at 1 to 10 μ M it did not affect the surface of E. coli strains17. 
Nevertheless, increasing the concentration of this peptide to 100 μ M led to evident morphological damage, 
including bacterial surface disruption. However, as for Pa-MAP 1.9, such a high concentration was not required 
for the lethal activities of this peptide.
The results obtained in the AFM experiments encouraged us to study the ability of Pa-MAP 1.9 to interact 
with lipid vesicles mimicking different types of biological membranes. Pa-MAP 1.9 was effective in disrupting 
Figure 3. Leakage experiments performed with increasing concentrations of Pa-MAP 1.9 against large 
unilamellar vesicles. Percentage of carboxyfluorescein release (CF) in unilamellar vesicles composed of 
different proportions of POPC, POPG, POPS, LPS and cholesterol induced by different peptide concentration, 
ranging from 0.0 to 0.3 μ M (a) and from 0.0 to 1 μ M (b).
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vesicles constituted with some proportion of anionic lipids such as POPS, POPG and LPS. However, as antici-
pated based on our bioassays, much higher concentrations were necessary for the disruption of vesicles composed 
Figure 4. Circular dichroism analysis of Pa-MAP 1.9. CD spectra of Pa-MAP 1.9 solubilized in water (pH 
3–11) (a) TFE 50% (v:v; pH 3–11) (b) and SDS 28 mM (pH 3–11) (c) Higher helical contents (ellipticity) were 
obtained/calculated at pH 11, highlighted as dashed lines in all conditions.
Figure 5. BLASTp analysis, predicted secondary structure and electrostatic potential of Pa-MAP 1.9. 
Alignment between the query (Pa-MAP 1.9) and template (PDB: 1wfa) primary sequences, highlighting 
(yellow) the identical residues (a). Lowest free-energy three-dimensional theoretical model for Pa-MAP 1.9: 
in white, non-polar residues; in pink, polar residues; in cyan, basic residues (b). Adaptive Poisson-Boltzmann 
solver (APBS) electrostatic potential of Pa-MAP 1.9; potential ranges from − 10.9 kT/e (red) to + 10.1 kT/e 
(blue) (c).
www.nature.com/scientificreports/
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solely of zwitterionic or neutral phospholipids (e.g., POPC and cholesterol). Furthermore, cholesterol-containing 
membranes could not be significantly disrupted even at the highest concentrations tested. Apparently, cholesterol 
which is present in mammalian cells assists in the stability of these membranes24. Pa-MAP 1.9 lipid-selective 
disruption of biomembrane model systems was also consistent with our bioassays, wherein this peptide clearly 
presented better activities against Gram-negative bacteria, which contains a more anionic surface based on lipid 
composition. In addition, the observation that Pa-MAP 1.9 revealed no cytotoxicity against different mamma-
lian cell lines could have been related in part to its inability to disrupt neutral (zwitterionic) phospholipids and 
cholesterol-containing membranes. Lee and colleagues25 observed similar results in studying detergent-like mem-
brane disruption by four magainin analogues, namely MSI-78, MSI-367, MSI-594 and MSI-843. In this context, 
by using solid-state nuclear magnetic resonance (NMR), the authors concluded that MSI peptides fragmented 
LUVs by using a detergent-like process. As described here for Pa-MAP 1.9, MSI peptides were able to disrupt 
anionic (POPG; POPS) LUVs at much lower concentrations than zwitterionic (POPC) LUVs. However, when 
cholesterol was present in the lipid vesicle composition, the disruptive potential of these peptides drastically 
decreased.
Similarly, in molecular docking simulations, the complex of Pa-MAP 1.9 with POPC/POPS revealed improved 
affinity values and a larger number of atomic interactions of different types (hydrogen and saline bonds), when 
compared to the Pa-MAP 1.9 complex with POPC/Cholesterol (Table 2). In a recent work, the parent peptide 
Pa-MAP was predicted to form hydrophobic interactions with a DPPC membrane with a lower affinity value 
(− 3.1 kcal.mol−1), when compared with the results here22. Comparing the primary sequences of Pa-MAP and 
Pa-MAP 1.9, it was possible to observe a decrease in the hydrophobic residue content of Pa-MAP 1.9 (64%) when 
compared to Pa-MAP (73%), which is due to the substitution of Pa-MAP hydrophobic residues by hydrophilic 
ones in Pa-MAP 1.9. Similarly this was reflected in the hydrophobic moment of Pa-MAP 1.9, which was higher 
when compared to Pa-MAP, being 0.26 and 0.10 on the Eisenberg scale, respectively26. Furthermore, due to the 
addition of four lysine residues (Lys4, Lys7, Lys11 and Lys18) 1.9 had a net charge of + 4, which made this peptide 
much more cationic than its precursor (net charge = − 1), favouring its interaction with bacterial membranes. 
Figure 6. Graphical representation of physicochemical parameters resulted from molecular dynamics 
simulations. Pa-MAP 1.9 molecular dynamics simulations in water (a), TFE 50% (v:v) (b) and SDS micelle (c), 
yielding the parameters root mean square deviation (RMSD), root mean square fluctuation (RMSF), solvent-
surface accessible area (SASA) and radius of gyration (Rg) for each conditions.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:21385 | DOI: 10.1038/srep21385
Figure 7. Three-dimensional theoretical structures snapshots of Pa-MAP 1.9 during 100 ns of molecular 
dynamics simulation. Evaluations were performed in water (a), TFE 50% (v:v) (b) and SDS micelle (c). The 
N-terminal region of the peptide is always at the bottom (top).
Figure 8. In silico interactions between Pa-MAP 1.9 and anionic/zwitterionic mimetic membranes. Three-
dimensional theoretical representation of the complexes Pa-MAP 1.9–POPC/POPS (50:50) (A) and Pa-MAP 
1.9–POPC/Chol (70:30) (B), as well as zoom images, revealing the amino acids residues from Pa-MAP 1.9 
(yellow sticks) possibly involved in interactions with the phospholipids (white sticks) from both POPC/POPS 
(C) and POPC/Chol (D) mimetic membranes.
www.nature.com/scientificreports/
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In addition, the positioning of the amino acid residues of Pa-MAP 1.9 was designed to allow a more efficient 
distribution of hydrophobic and positively charged faces, favoring the amphipathicity of the molecule, as well as 
distributing alanine residues more evenly along the entire peptide, increasing the probability of helical structur-
ing. These characteristics of Pa-MAP 1.9 would provide a major driving force for α -helix insertion into anionic 
bilayers, causing their perturbation, as well as entropy loss due to peptide loss of water interactions caused by 
translocation into the membrane and consequent α -helix structuring, as observed previously for other polyala-
nine peptides27.
Structurally, the CD spectra of Pa-MAP 1.9 revealed a well-defined α -helix conformation in the presence 
of SDS or 50% TFE. Similarly, Perrin and colleagues28 described the CD spectrum of piscidins 1 and 3 which, 
in the presence of anionic vesicles (POPC/POPG 3:1 and POPE/POPG 1:1), tend to become arranged into 
α -helical structures. In water, however, Campagna and co-workers19 reported that piscidins 1 had an unstruc-
tured conformation, also observed by NMR spectroscopy. Consistent with this work, when Pa-MAP 1.9 was 
solubilized in water, independently of the pH, a random conformation could be observed. These events could 
also be three-dimensionally visualized in our molecular dynamics simulations, whereby Pa-MAP 1.9 presented a 
well-defined α -helix conformation when in 50% TFE and in contact with an SDS micelle, but a coil conformation 
with a small, central α -helix in water. These features are consistent both with other AMPs from polar fishes as 
with the polyalanine precursor Pa-MAP12. Such environment-dependent behavior is important not only for the 
understanding of membrane-based mechanisms of action, but also are crucial for the elucidation of how AMPs 
reorient, insert into and translocate across membranes to act on intracellular targets.
In summary, Pa-MAP 1.9 proved to be a useful candidate for the treatment of Gram negative bacteria infec-
tions, especially in their biofilm state. It works through a dose-dependent mechanism of action, without being 
hemolytic and cytotoxic against mammalian cells. We also demonstrated that Pa-MAP 1.9 was able to interact 
with bacterial mimetic membranes and vesicles, adopting a well-defined α -helical conformation that might favor 
Pa-MAP 1.9 orientation and insertion into lipid bilayers to perform its activities.
Material and Methods
Pa-MAP 1.9 synthesis and mass spectrometry analysis. Pa-MAP 1.9 was purchased from Peptide 
2.0 Incorporated (USA), which synthesized the peptide at 95% purity (after TFA removal) by the stepwise sol-
id-phase method using the N-9-fluorenylmethyloxycarbonyl (Fmoc) chemistry on a Rink amide resin. Pa-MAP 
1.9 molecular mass was confirmed by MALDI-ToF MS/MS analysis (Autoflex, Bruker Daltonics, Billerica, MA). 
The synthetic peptide concentrations for all in vitro experiments were determined using the measurement of 
absorbance at 205, 215 and 225 nm.
In vitro antimicrobial assays. For antimicrobial assays, strains of E. coli (ATCC 8739, KPC 001812446 and 
KPC 002101123), K. pneumoniae (KPC 001825971, KPC 002210477 and ATCC 13883), E. faecalis (ATCC 19433), 
P. aeruginosa (ATCC 27853) and S. aureus (ATCC 25923) were grown in Luria Bertani (LB) broth overnight, at 
37°C. MIC measurements were performed in LB medium with 5 × 106 CFU and dilutions of Pa-MAP 1.9 from 
0.7 to 115 μ M. MIC was assessed as the minimal 100% inhibitory concentration of peptide after 12 h of incuba-
tion at 37 °C. During this period, the absorbance was measured in a plate reader (Bio-Rad 680 Microplate Reader) 
at 595 nm every 30 min. Bacteria in LB medium and in several dilution of chloramphenicol were used as negative 
and positive controls, respectively. All experiments were performed in triplicate.
Pa-MAP 1.9
Distances 
(Å)
POPC/POPS (50:50)
InteractionsResidues Positions
Atom 
Names Lipids Positions
Atom 
Names
Leu 1 N 3.6 POPS 27 O14 HB
Lys 4 NZ 3.5 POPC 10 O14 SB
Lys 7 NZ 3.6 POPC 18 O13 SB
Thr 10 OG1 3.1 POPS 6 O13 HB
Lys 11 NZ 3.6 POPS 6 O13 SB
Lys 11 O 3.3 POPS 3 N HB
Ala 15 O 3.5 POPS 2 O13 HB
Lys 18 NZ 3.5 POPS 4 O13 SB
Lys 18 O 3.5 POPS 4 O13 HB
Ala 22 O 2.8 POPS 9 O13 HB
Pa-MAP 1.9 POPC/Chol (70:30)
Ala 2 O 2.7 Chol 7 O3 HB
Thr 6 OG1 3.0 Chol 7 O3 HB
Thr 10 OG1 2.8 Chol 2 O3 HB
Thr 13 OG1 3.4 Chol 9 O3 HB
Thr 17 O 3.2 Chol 15 O3 HB
Thr 28 OG1 2.7 Chol 50 O3 HB
Table 2.  In silico predicted interactions between Pa-MAP 1.9 and anionic/zwitterionic mimetic 
membranes revealing the types and distances of atomic interactions occurring in these complexes. 
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Anti-biofilm assays. Dilutions (1/100) of overnight cultures of E. coli (ATCC O157) and K. pneumoniae 
(KPC 001825971) grown overnight in LB medium were incubated in basal medium 2 (BM2) [62 mM potassium 
phosphate buffer (pH 7), 7 mM (NH4)2SO4, 2 mM MgSO4, 10 μ M FeSO4, 0.5% glucose], in 96-well cell culture 
cluster round bottom microplate in the presence of Pa-MAP 1.9 for 24 h at 37 °C. Positive growth control con-
tained only bacteria, and negative control wells contained broth only. Afterwards, planktonic cells were removed 
and microplate wells were washed twice with deionized water. The attached bacteria remaining were stained with 
100 μ L of 0.1% (m/v) crystal violet for 20 min. The microplates was rinsed twice with deionized water, air-dried 
and resolubilized with 110 μ L of ethanol 70%. The content of the microplate was transferred to a new microplate, 
and the MBIC of Pa-MAP 1.9 was accessed at 595 nm in a microtiter plate reader (Bio-Tek Instruments Inc., VT).
Flow cell assays. Biofilms were grown for 72 h, at 37 °C in flow chambers with channel dimensions of 1 by 
4 by 40 mm, as previously described29. For treatment of pre-formed biofilms, bacteria were allowed to develop 
structured 2-day-old biofilms prior to treatment with Pa-MAP 1.9, for the following 24 h. The medium used to 
allow biofilm growth was (BM2) containing 0.4% (wt/vol) glucose as a carbon source. Silicone tubing (VWR, 
0.062 in ID by 0.125 in OD by 0.032 in wall) was autoclaved, and the system was assembled and sterilized by 
pumping a 0.5% hypochlorite solution through the system at 6 rpm for 30 min using a Watson Marlow 205S 
multi-channel peristaltic pump. The system was then rinsed at 6 rpm with sterile water and medium for 30 min 
each. Flow chambers were inoculated by injecting 400 μ l of an overnight culture diluted at 1:25 (v/v). After inoc-
ulation, chambers were left without flow for 2 h, after which medium was pumped through the system at a con-
stant rate of 0.5 rpm for 48 h. After this time, treatments were diluted in BM2 medium at desired concentration 
and pumped through the system for 24 h. Biofilm cells were stained using the LIVE/DEAD BacLight Bacterial 
Viability kit (Molecular Probes, Eugene, OR) prior to microscopy experiments. A ratio of SYTO-9 (green fluo-
rescence, live cells) to propidium iodide (PI) (red fluorescence, dead cells) of 1:5 was used. Microscopy was done 
using a confocal laser-scanning microscope (Olympus, Fluoview FV1000) and three-dimensional reconstructions 
were generated using the Imaris software package (Bitplane AG).
Hemolytic assay. The hemolytic activity of Pa-MAP 1.9 was assessed by using human erythrocytes 
approved by the ethics committee of FEPECS (number: 396.061) and registered in Brazil Platform (number: 
16131213.0.0000.5553), according with the approved guidelines. The cells were stored at 4 °C. Erythrocytes were 
washed three times with 50 mM phosphate buffer, pH 7.4. The peptide solution was added to the erythrocyte 
suspension (1%, by volume), at a final concentration ranging from 0.7 to 115 mM in a final volume of 100 mL. 
Samples were incubated at room temperature for 60 min. Hemoglobin release was monitored by measuring the 
supernatant absorbance at 540 nm. Zero hemolysis control (blank) was determined with erythrocytes suspended 
in the presence of 50 mM phosphate buffer, pH 7.4, and for positive control (100% of erythrocyte lyses); an aque-
ous solution of 1% (by volume) triton X-100 dissolved in distilled water was used instead of the peptide solution. 
Hemolytic assays were performed in triplicate.
Cytotoxicity assays. For the cytotoxic assays, confluent RAW 264.7 (mouse leukemic monocyte mac-
rophage) cell line was challenged with 0.7 to 115 μ M of Pa-MAP 1.9 and incubated at 37 °C in a 5% CO2 atmos-
pheres for 48 h, according to previously described methodology12. Experiments were performed in triplicate and 
cells imaged using an inverted optical microscope (Leitz) in order to describe morphological alterations. The 
neutral red dye-uptake method30 was used to evaluate cell viability. Cells were incubated in the presence of 0.01% 
(by weight) neutral red solution for 3 h at 37 °C in a 5% CO2 atmosphere. After, the medium was removed and the 
cells were fixed with 4% formalin in phosphate-buffered saline, pH 7.2. The dye, incorporated by the viable cells, 
was eluted by using a mixture of methanol:acetic acid:water (50:1:49,v:v:v), and the dye uptake was determined 
by measuring the absorbance at 490 nm in an automatic spectrophotometer (ELx800 TM-Bio-TeK Instruments, 
Inc.). The cytotoxic assays were performed in triplicate.
Bacteria preparation and atomic force microscopy imaging. The effects of Pa-MAP 1.9 on E. coli 
(ATCC 25922) were evaluated by AFM imaging as previously described31,32. Bacterial cells were incubated with 
Pa-MAP 1.9 at 0, 6 and 300 μ M in growth broth, at 37 °C, for 1 h. A 100 μ L droplet of each sample was applied 
onto poly-L-lysine-coated glass slide and left at 25 °C for 30 min. After deposition, the sample was rinsed 10 times 
with Milli-Q water, and left to air-dry. AFM images were obtained on a JPK Instruments NanoWizard II (Berlin, 
Germany) mounted on a Carl Zeiss Axiovert 200 inverted microscope (Jena, Germany). Images were performed 
in intermittent contact mode (air) using ACL silicon cantilevers from AppNano (Huntingdon, UK) with a tip 
radius of 6 nm, a resonant frequency of approximately 190 kHz and a spring constant of 58 N m−1. All images were 
obtained with similar AFM parameters (setpoint, scan rate and gain values). The scan rate was set between 0.3 
and 0.6 Hz and the setpoint was close to 0.3 V. Height and error signals were collected and images were analyzed 
with the JPK image processing software v. 5.1.13.
LUV preparation and leakage assays. Large unilamellar vesicles with ~100 nm of diameter were 
obtained by extrusion of multilamellar vesicles, as described elsewhere33. POPC, POPG and POPS were obtained 
from Avanti Polar Lipids (Alabaster, AL), while LPS (E. coli O26:B6) and cholesterol (Chol) were obtained from 
Sigma (St. Louis, MO). The LUVs studied were zwitterionic (pure POPC and POPC:Chol 70:30) or anionic 
(POPC:POPG 80:20, POPC:POPG 50:50, pure POPG, POPC:POPS 80:20, POPC:POPS 50:50, POPC:LPS 80:20 
and POPC:POPG:LPS 50:30:20). For lipid film formation with LPS, it was dissolved in chloroform:methanol (2:1) 
and the solution was vortexed and bath sonicated at 40 °C for 15 min. Stock solutions were kept at 4 °C overnight 
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before measurements. Phosphate buffer saline (20 mM sodium phosphate, 150 mM NaCl) pH 7.4 was used for 
these measurements.
Peptide-induced lipid vesicle leakage was measured as previously described13, by fluorescence spectroscopy, 
on a Varian Cary Eclipse fluorescence spectrophotometer (Mulgrave, AU). In this assay, we monitored the release 
of 5,(6)-carboxyfluorescein (CF; Sigma, St. Louis, MO), trapped in the LUV. LUVs were prepared as described 
above, with dried film hydration in phosphate buffered saline (PBS) containing 100 mM CF (pH was adjusted 
to 7.4 with NaOH). Free CF was removed by passing the suspension through an EconoPac 10 DG column from 
Bio-Rad (Richmond, CA), where the vesicles are eluted with the void volume13. Aliquots of the liposomal stock 
preparations (diluted to 10 μ M) were incubated with different concentrations of the peptide at 25 °C. Fluorescence 
was recorded continuously for 30 min, with excitation at 492 nm and emission at 517 nm (5 and 10 nm excitation 
and emission slits, respectively).
Circular dichroism. CD measurements were performed on a JASCO J-815 spectropolarimeter (Easton, 
MD), equipped with a Peltier-type temperature controller and a thermostable cell holder, also interfaced with 
a thermostatic bath. Spectra were recorded in 0.1 cm path length quartz cells at a peptide concentration rang-
ing from 0.05 to 0.5 mg.mL−1 in 2 mM Na-acetate buffer at pH 3.0, 2 mM Na-acetate buffer at pH 4.0, 2 mM 
Na-acetate buffer at pH 5.5, deionized water (Milli-Q), 2 mM Tris-HCl buffer at pH 7.0, 2 mM Tris-HCl buffer 
at pH 8.5, 2 mM glycine-NaOH buffer at pH 10.0 and 2 mM glycine-NaOH buffer at pH 11.0. Four consecutive 
scans were accumulated and the average spectra stored. Pa-MAP 1.9 analysis in the presence of SDS and TFE were 
performed in the same quartz cell with a 0.1 cm path length at 20 °C. The spectra were recorded between 190 and 
260 nm at a scan speed of 50 nm.min−1 and four scans were performed per sample. The spectra were recorded in 
three average environments: distilled water, 28 mM SDS and TFE 50% in water (v:v). The observed ellipticity was 
converted into the mean residue ellipticity [θ ] based on a mean molecular mass per residue of 115 Da. The data 
were corrected for the baseline contribution of the buffer and the observed ellipticities at 222 nm were recorded. 
The α -helical content of the peptides was calculated from mean residual ellipticity at 222 nm ([θ ]222) using the 
following equation: fH = [θ ]222/[− 40,000(1 − 2.5/n)], where fH and n represent the α -helical content and the 
number of peptide bonds, respectively34. All spectra were acquired at 37 °C.
Molecular Modelling. Initially, BLASTp35 was performed in order to find the best primary sequence tem-
plate for molecular modelling. After that, 200 theoretical three-dimensional models were constructed by using 
Modeller v. 9.1236, based on an antifreeze peptide primary sequence (PDB code: 1WFA) isolated from P. amer-
icanus. The lowest free-energy theoretical model for Pa-MAP 1.9 was then selected and used for validation 
procedures. Firstly, PROCHECK14 evaluated peptide’s geometry, stereochemistry and energy distribution, also 
calculating its average score for dihedral angles, jointly with covalent forces. Moreover, 3DSS37 was also used for 
(RMSD) calculation by superimposing Cα -traces and backbones of both theoretical and template tridimensional 
structures.
Molecular Dynamics. The molecular dynamics simulations for the Pa-MAP1.9 were carried out in three 
different steps. The first one was performed in water; the second one in water and TFE 50%/50% (volume/vol-
ume) and, the third one was carried out in water with an anionic environment (SDS micelle). All simulations 
were performed by using the computational package GROMACS v.438 with the GROMOS96 43A1 force field 
implemented. As initial structure for dynamics simulations the best tridimensional theoretical model of Pa-MAP 
1.9 was used, which was immersed in 7,897 water molecules in a cube box with sides measuring 6.22 nm. In order 
to neutralize the system’s charge, chloride ions were also added (four ions in this case). TFE 50% simulation was 
carried out with 1,892 and 2,023 water molecules, as well as 459 and 354 TFE molecules in a cube box with sides 
measuring 4.78 nm. The final step (SDS) was carried out in a dodecahedral box with a minimum distance of 
0.7 nm between the non-water molecules and the box's frontiers. In this case, Pa-MAP 1.9, a SDS micelle with 
128 phospholipid residues, 13,021 water molecules and chlorine ions constituted the system. Geometry of water 
and water/TFE 50% molecules was constrained using the SETTLE algorithm39. Moreover, the LINCS algorithm 
was used to link all the atom bond length. Particle Mesh Ewald (PME) was also used for electrostatic corrections, 
with a radius cut-off of 1.4 nm in order to minimize the computational simulation time. The same radius cut off 
was also used for van der Waals interactions. The list of neighbors of each atom was updated every 10 simulation 
steps of 2 fs each. A conjugate gradient (2 ns) and the steepest descent algorithms (2 ns) were implemented for 
energy minimization. After that, the system underwent a normalization of pressure and temperature, using the 
integrator stochastic dynamics (SD), 2 ns each. The system with minimized energy and balanced temperature 
and pressure was carried out using a step of position restraint, using the integrator Molecular Dynamics (MD), 
for 2 ns. The simulations were carried out at 27 °C in silico, aiming to understand the structural conformation of 
the peptide more nearly to that observed in vitro bioassays. The total time of Pa-MAP 1.9 simulation was 100 ns, 
in triplicate.
Molecular Docking. For molecular docking studies, the program AUTODOCK 4.240 was used in order to 
predict the possible modes of interaction between Pa-MAP 1.9 and anionic as well as zwitterionic mimetic mem-
branes, based on what was done in the leakage experiments. For this, the CHARMM-GUI41 server was used 
for membrane construction, constituted of POPC/POPS (50:50) (anionic environment) and POPC/cholesterol 
(70:30) (zwitterionic environment), with 75 × 75 × 45 Å3 of dimension. Moreover, by using AutoDock Tools, 
all the hydrogen atoms were added and a grid box of 60 × 60 × 20 points with spacing of 1.0 Å was centered 
on the membrane surfaces. Furthermore, AutoDock Tools were also used for peptide manipulation, where the 
maximum freedom to side chains was unlocked. The molecular docking simulations were programed for fifty 
random runs, with the generated structures being ranked based on their affinity values in kcal.mol−1. After all 
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simulations, PyMOL was used to predict peptide-membrane interactions, respecting the distance of 3.6 Å for all 
atoms involved.
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